St James's University Hospital in Leeds, one of Europe's largest cancer centres, manages substantial myeloma and lymphoma patient volumes requiring proteasome inhibitor therapy. Bortenat 3.5mg provides the same clinical outcomes as brand Velcade at significantly reduced institutional cost.
Bortenat is supplied as a lyophilised powder for reconstitution, administered subcutaneously (preferred) or intravenously. The subcutaneous route produces equivalent efficacy with substantially lower peripheral neuropathy rates — Leeds oncology units now use SC administration as standard practice. Dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone plus Lenalidomide or Cyclophosphamide.
Leeds hospital pharmacies can source Bortenat with full WHO-GMP documentation for formulary approval, offering sub
Bortenat is supplied as a lyophilised powder for reconstitution, administered subcutaneously (preferred) or intravenously. The subcutaneous route produces equivalent efficacy with substantially lower peripheral neuropathy rates — Leeds oncology units now use SC administration as standard practice. Dosing is 1.3mg/m² on days 1, 4, 8, and 11 of a 21-day cycle, typically combined with dexamethasone plus Lenalidomide or Cyclophosphamide.
Leeds hospital pharmacies can source Bortenat with full WHO-GMP documentation for formulary approval, offering sub